ASX Health Stocks: Immuron reports record sales for its diarrhoea drug, Travelan

Immuron reports record sales for Travelan in January
Neurotech extends Phase 1/2 clinical trial for benefit of patients

Immuron’s record sales

Immuron (ASX:IMC) has just announced record sales (unaudited) for Travelan for the January period.

Year to date January sales were $2.7 million in total, which exceeded the peak full year FY20 sales of $2.5 million.

In Australia, sales of Travelan increased to $2.1 million in January, compared to $0.3 million in the pcp.

Travelan is an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. It’s an orally administered immunotherapy that reduces the likelihood of contracting travelers’ diarrhoea.

Immuron previously reported that it had shipped inventory to Amazon for launch in US. The Amazon launch continues to progress well with sales ahead of budget.

Travelan is also a listed medicine on the Australian Register for Therapeutic Goods.

“We hope to get similar growth of the brand as we increase our investment and distribution in North America during the spring and summer vacation peak period,” said Immuron’s chief commercial officer, Flavio Palumbo.

Neurotech extends study

Meanwhile, Neurotech International (ASX:NTI) announced Human Research Ethics Committee (HREC) approval to extend its Phase I/II clinical trial in autism spectrum disorder (ASD) by another 52 weeks in total.

The extension was based on requests from the company’s lead investigator, patients and their caregivers, to continue to extend the duration of treatment for these patients.

The Phase 1/2 clinical trial examines the daily use of Neurotech’s proprietary broad spectrum cannabinoid drug therapy, NTI164.

Results so far found that NTI164 continues to exhibit a safety and tolerability profile, with all patients showing stable blood chemistries and normal liver and kidney function.

The trial is the longest ever study in ASD, examining the safety of a broad spectrum cannabinoid drug treatment.

Data from this trial will support future regulatory interactions and filings for NTI64.

“We continue to focus our resources on completing the current Phase II/III ASD trial and remain on track to report the results of our Phase II/III ASD trial in late Q1 2024, to early Q2 2024,” said Dr Thomas Duthy, executive director of Neurotech.